Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility

Página do item simplificado
dc.contributor.authorFranco Junior, Jose Gonçalves [UNESP]
dc.contributor.authorOliveira, Joao Batista A [UNESP]
dc.contributor.authorPetersen, Claudia G [UNESP]
dc.contributor.authorMauri, Ana L. [UNESP]
dc.contributor.authorBaruffi, Ricardo LR [UNESP]
dc.contributor.authorCavagna, Mario [UNESP]
dc.contributor.institutionCenter for Human Reproduction
dc.contributor.institutionResearch and Training
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:25:58Z
dc.date.available2014-05-27T11:25:58Z
dc.date.issued2011-09-01
dc.description.abstractInfertility represents one of the main long-term consequences of combination chemotherapy used for the treatment of breast cancer. Approximately 60%-65% of breast cancers express the nuclear hormone receptor in premenopausal women. Adjuvant endocrine therapy is an integral component of care for patients with hormone receptor-positive (HR+) tumours. The GnRH agonist (GnRHa) alone or in combination with tamoxifen produces results at least similar to those obtained with the different chemotherapy protocols in patients with HR+ tumors with respect to recurrence-free survival and overall survival, Presentation of the hypothesis: It is time to indicate adjuvant therapy with GnRHa associated with tamoxifen for patients with breast cancer (HR+ tumours) if they want to preserve their reproductive function. Testing the hypothesis: Assessment of ovarian reserve tests: follicle stimulating hormone (FSH), anti-Mullerian hormone (AMH), inhibin B, antral follicle count (AFC) and ovarian volume 6 months, and 1 year after the end of therapy with GnRHa/tamoxifen. The recurrence-free survival and overall survival should be analysed. Implications of the hypothesis: The major implication will be to avoid adjuvant chemotherapy for patients with breast cancer (HR+ tumours) that request fertility preservation. It is expected that ovarian function should not be altered in almost all cases. © Todos os direitos reservados a SBRA - Sociedade Brasileira de Reprodução Assistida.en
dc.description.affiliationCenter for Human Reproduction, Ribeirao Preto
dc.description.affiliationPaulista Center for Diagnosis Research and Training, Ribeirao Preto
dc.description.affiliationDepartment of Gynecology and Obstetrics Botucatu Medical School São Paulo State University - UNESP, Botucatu
dc.description.affiliationUnespDepartment of Gynecology and Obstetrics Botucatu Medical School São Paulo State University - UNESP, Botucatu
dc.format.extent39-43
dc.identifierhttp://www.jbra.com.br/mensagem/pub/mensagem.php?id_mensagem=custom_arquive&lingua_atual=_ing
dc.identifier.citationJornal Brasileiro de Reproducao Assistida, v. 15, n. 5, p. 39-43, 2011.
dc.identifier.issn1517-5693
dc.identifier.issn1518-0557
dc.identifier.scopus2-s2.0-80052392800
dc.identifier.urihttp://hdl.handle.net/11449/72626
dc.language.isoeng
dc.language.isopor
dc.relation.isnodouble11856*
dc.relation.ispartofJornal Brasileiro de Reproducao Assistida
dc.relation.ispartofsjr0,282
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectAdjuvant therapy
dc.subjectBreast cancer
dc.subjectChemotherapy
dc.subjectFertility preservation
dc.subjectGnRHa
dc.subjectHormone receptor-positive
dc.subjectTamoxifen
dc.subjectCyclophosphamide
dc.subjectFluorouracil
dc.subjectFollitropin
dc.subjectGonadorelin agonist
dc.subjectHormone receptor
dc.subjectInhibin B
dc.subjectMethotrexate
dc.subjectMuellerian inhibiting factor
dc.subjectTamoxifen
dc.subjectAdjuvant therapy
dc.subjectAmenorrhea
dc.subjectBreast cancer
dc.subjectDisease association
dc.subjectDisease free survival
dc.subjectFertility
dc.subjectHuman
dc.subjectHypergonadotropism
dc.subjectOvarian reserve
dc.subjectOvary function
dc.subjectOvary insufficiency
dc.subjectOverall survival
dc.subjectReproduction
dc.titleAdjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertilityen
dc.title.alternativeA terapêutica adjuvante com agonista do GnRH/tamoxifeno no cancer de mama pode ser um bom conselho para os pacientes com tumors receptor-hormonal positivos e desejo de preservar a fertilidadept
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Coleções

Artigos - Ginecologia e Obstetrícia - FMB